Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Anti-ApoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals

Lagerstedt, J. O. LU ; Dalla-Riva, J. LU ; Marinkovic, G. LU ; Del Giudice, R. LU ; Engelbertsen, D. LU ; Burlin, J. ; Petrlova, J. LU ; Lindahl, M. LU ; Bernfur, K. LU and Melander, O. LU orcid , et al. (2019) In Journal of Internal Medicine 285(1). p.49-58
Abstract

Objective: IgG antibodies against apolipoprotein A-I (ApoA-I) have been found to be elevated in subjects from the general population with clinically manifest cardiovascular disease and in myocardial infarction patients with an adverse prognosis. Here, we investigated whether these antibodies are prospectively associated with carotid artery disease progression and with the risk for first-time cardiovascular events in individuals with no previous history of cardiovascular disease. Approach and results: We selected 383 subjects from the cardiovascular cohort of Malmö Diet and Cancer study who suffered a coronary event during a median follow-up period of 15.4 (10.3–16.4) years and 395 age- and sex-matched controls. None of the study... (More)

Objective: IgG antibodies against apolipoprotein A-I (ApoA-I) have been found to be elevated in subjects from the general population with clinically manifest cardiovascular disease and in myocardial infarction patients with an adverse prognosis. Here, we investigated whether these antibodies are prospectively associated with carotid artery disease progression and with the risk for first-time cardiovascular events in individuals with no previous history of cardiovascular disease. Approach and results: We selected 383 subjects from the cardiovascular cohort of Malmö Diet and Cancer study who suffered a coronary event during a median follow-up period of 15.4 (10.3–16.4) years and 395 age- and sex-matched controls. None of the study participants had a previous history of coronary artery disease or stroke. Anti-ApoA-I IgG were measured by ELISA in serum samples collected at baseline. Intima-media thickness (IMT) was measured in the common carotid artery and in the carotid bifurcation at baseline and after 15.9 (±1.5) years. We found no associations between anti-ApoA-I IgG and carotid artery IMT at baseline or with IMT progression during follow-up. In Cox proportional hazards analyses adjusted for traditional cardiovascular risk factors, the hazard ratio (HR 95%CI) for the primary outcome, incident coronary events, was 0.97 (0.75–1.25), P = 0.782, in subjects with anti-ApoA-I IgG within the highest tertile compared with the lowest tertile. Similarly, we did not find any associations with the secondary outcome, incident first-time stroke. Conclusions: Serum autoantibodies against ApoA-I do not correlate with disease progression and adverse events in cardiovascular disease-free individuals from the general population.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
apolipoprotein A-I, autoantibodies, carotid intima-media thickness, coronary artery disease, HDL
in
Journal of Internal Medicine
volume
285
issue
1
pages
49 - 58
publisher
Wiley-Blackwell
external identifiers
  • pmid:30028049
  • scopus:85052640508
ISSN
0954-6820
DOI
10.1111/joim.12817
language
English
LU publication?
yes
id
e8c6a0c7-d1bd-4592-98d0-5694b034926d
date added to LUP
2018-09-27 14:29:59
date last changed
2024-03-13 10:38:12
@article{e8c6a0c7-d1bd-4592-98d0-5694b034926d,
  abstract     = {{<p>Objective: IgG antibodies against apolipoprotein A-I (ApoA-I) have been found to be elevated in subjects from the general population with clinically manifest cardiovascular disease and in myocardial infarction patients with an adverse prognosis. Here, we investigated whether these antibodies are prospectively associated with carotid artery disease progression and with the risk for first-time cardiovascular events in individuals with no previous history of cardiovascular disease. Approach and results: We selected 383 subjects from the cardiovascular cohort of Malmö Diet and Cancer study who suffered a coronary event during a median follow-up period of 15.4 (10.3–16.4) years and 395 age- and sex-matched controls. None of the study participants had a previous history of coronary artery disease or stroke. Anti-ApoA-I IgG were measured by ELISA in serum samples collected at baseline. Intima-media thickness (IMT) was measured in the common carotid artery and in the carotid bifurcation at baseline and after 15.9 (±1.5) years. We found no associations between anti-ApoA-I IgG and carotid artery IMT at baseline or with IMT progression during follow-up. In Cox proportional hazards analyses adjusted for traditional cardiovascular risk factors, the hazard ratio (HR 95%CI) for the primary outcome, incident coronary events, was 0.97 (0.75–1.25), P = 0.782, in subjects with anti-ApoA-I IgG within the highest tertile compared with the lowest tertile. Similarly, we did not find any associations with the secondary outcome, incident first-time stroke. Conclusions: Serum autoantibodies against ApoA-I do not correlate with disease progression and adverse events in cardiovascular disease-free individuals from the general population.</p>}},
  author       = {{Lagerstedt, J. O. and Dalla-Riva, J. and Marinkovic, G. and Del Giudice, R. and Engelbertsen, D. and Burlin, J. and Petrlova, J. and Lindahl, M. and Bernfur, K. and Melander, O. and Nilsson, J. and Schiopu, A.}},
  issn         = {{0954-6820}},
  keywords     = {{apolipoprotein A-I; autoantibodies; carotid intima-media thickness; coronary artery disease; HDL}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{49--58}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{Journal of Internal Medicine}},
  title        = {{Anti-ApoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals}},
  url          = {{http://dx.doi.org/10.1111/joim.12817}},
  doi          = {{10.1111/joim.12817}},
  volume       = {{285}},
  year         = {{2019}},
}